zlatkopaisley1275.blogspot.com
Thomas Kodadek and a team developexd the technology while atthe . He recentlgy joined the faculty at in Jupiter and will become a consultantto Miami-basexd Opko, (AMEX: OPK), where he will oversee the developmeny of the newly acquired technology. Opko, which is developin g drugs forophthalmic disease, will initially use the technology to develolp blood tests for several diseases that are not availabl and for which early diagnosis is difficult, Chairman and CEO Dr. Phillipo Frost said in a press release.
“Wer plan to begin with tests for Alzheimer’ds disease, multiple sclerosis, Parkinson’s disease and lung said Frost, who is one of South Florida's most prominenf entrepreneurs with a net worthb estimatedat $1.7 billion by Forbes. He previousluy led and Key Pharmaceuticals. Sharesw of Opko were up a penny in mornintg tradingto $1.43. No 52-weel high/low was available.
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment